




RealRate

PHARMACEUTICAL 2019

Karyopharm Therapeutics Inc.
Rank 221 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2019

Karyopharm Therapeutics Inc. Rank 221 of 371



The relative strengths and weaknesses of Karyopharm Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Karyopharm Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 112% points. The greatest weakness of Karyopharm Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 120% points.

The company's Economic Capital Ratio, given in the ranking table, is -209%, being 122% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	334,612
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	46,904
Liabilities, Non-Current	0
Other Assets	2,717
Other Compr. Net Income	-27
Other Expenses	26
Other Liabilities	111,118
Other Net Income	1,502
Property and Equipment	3,863
Research and Development	161,372
Revenues	30,336
Selling, General and Administrative Expense	48,847

Output Variable	Value in 1000 USD
Assets	341,192
Liabilities	158,022
Expenses	210,245
Stockholders Equity	183,170
Net Income	-178,407
Comprehensive Net Income	-178,420
Economic Capital Ratio	-209%

